Next Article in Journal
Inadequate Intake of Dietary Fibre in Adolescents, Adults, and Elderlies: Results of Slovenian Representative SI. Menu Study
Next Article in Special Issue
Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria
Previous Article in Journal
The Effect of Weight-Loss Interventions on Cervical and Chin Subcutaneous Fat Depots; the CENTRAL Randomized Controlled Trial
Previous Article in Special Issue
Impact of Newborn Screening and Early Dietary Management on Clinical Outcome of Patients with Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency and Medium Chain Acyl-CoA Dehydrogenase Deficiency—A Retrospective Nationwide Study
 
 
Review
Peer-Review Record

Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs

Nutrients 2021, 13(11), 3828; https://doi.org/10.3390/nu13113828
by Terry G. J. Derks 1,*, David F. Rodriguez-Buritica 2, Ayesha Ahmad 3, Foekje de Boer 1, María L. Couce 4, Sarah C. Grünert 5, Philippe Labrune 6,7, Nerea López Maldonado 8,9, Carolina Fischinger Moura de Souza 10, Rebecca Riba-Wolman 11, Alessandro Rossi 1,12, Heather Saavedra 2, Rupal Naik Gupta 13, Vassili Valayannopoulos 13 and John Mitchell 14
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Nutrients 2021, 13(11), 3828; https://doi.org/10.3390/nu13113828
Submission received: 30 September 2021 / Revised: 21 October 2021 / Accepted: 22 October 2021 / Published: 27 October 2021
(This article belongs to the Special Issue Advances in Inherited Metabolic Disorders)

Round 1

Reviewer 1 Report

In this review manuscript, Derks et al. illustrated glycogen storage disease type Ia from epidemiology to the view of quality of life. The manuscript was well-written, and provided a lot of important information for the readers. However, several issues are still needed to clarified and revised. 

  1. Although the main concept is Glycogen storage disease type Ia, another types of glycogen storage disease are suggested to make a brief introduction and provide in the first paragraph of the manuscript.
  2. In lane 84-85, the authors indicated that there are a lot of factors increased blood glucose levels, but only insulin decreased blood glucose levels. Since the role of dysbiosis is important in glycogen storage disease type Ia, and glucagon like peptide-1 is another factor that decreases blood glucose, glucagon like peptide-1 is suggested to replenish in lane 84-85.
  3. In Current strategies for disease management section, the possible mechanisms for each diet for the treatment of  glycogen storage disease are encouraged to provide in this section. This would be helpful for researchers to develop novel therapeutic strategies for the treatment of glycogen storage disease.  

Author Response

Please see attachment

Author Response File: Author Response.docx

Reviewer 2 Report

good work, great informations

Author Response

Please see attachment

Author Response File: Author Response.docx

Reviewer 3 Report

I read with great interest your manuscript on GSD Ia wherein you describe the current management options with focus on the burden for patients and caregivers and the unmet needs.  The epidemiology; pathophysiology and clinical manifestations of this rare disease are very well described in a comprehensive manner.  The current strategy for disease management is described in detail, however I miss an overview of the therapeutic targets: can they be summarized in a table or box as you have done for the unmet needs and burden, encompassing biological (BMI) and biochemical targets (glycemia; lactic acid; serum triglycerides and total cholesterol,...) as this will be very helpful to caregivers, esp. specialized dietitians.  You mentioned (p5) vitamin B deficiency as one of the nutritional deficiencies: is this focusing on thiamine deficiency in particular?  Liver steathosis and adenomas are mentioned in the text: when and how frequent should the liver be examined for these complications and how (MRI?; ultrasonography?)?  Future directions are promising: does gene therapy also prevent kidney disease that is not achieved by liver transplantation (perhaps this cannot be answered at this moment as the clinical trials are still ongoing).

Author Response

Please see attachment

Author Response File: Author Response.docx

Back to TopTop